Stellapharma plans to issue 1,000,000 new shares and 10,500 stock acquisition rights to the allottee through a second third-party allotment in June 2026, raising approximately \u00a5779 million. The funds will be allocated to clinical trials for rare and deep-seated cancers and research and development efforts.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4888","jir_company_name":"Stellapharma Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4888-20260605-01.pdf","jir_short_summary":"Stellapharma plans to issue 1,000,000 new shares and 10,500 stock acquisition rights to the allottee through a second third-party allotment in June 2026, raising approximately \u00a5779 million. The funds will be allocated to clinical trials for rare and deep-seated cancers and research and development efforts.","jir_summary":"### Overview of Capital Policy\nStellapharma plans to issue new shares and stock acquisition rights to the allottee through a second third-party allotment in June 2026, raising approximately \u00a5779 million. The funds will be used for clinical trials and research on rare and deep-seated cancers, R&D, and overseas expansion. This aims to support future business expansion and establish a stable financial foundation. The issuance terms are set at 92% of the stock price, ensuring fair pricing. The post-issuance share dilution rate is judged to be within a reasonable range at 6.02%.\n\n### Future Outlook and Impact on Shareholders\nThe fundraising, with a relatively low dilution rate of 6.02%, aims to secure necessary funds for business expansion. The proceeds will be allocated to clinical trials and research on rare and deep-seated cancers, contributing to long-term corporate value enhancement. While shareholder ownership may be diluted, it is based on rationality of the fundraising and growth strategy, aiming to increase investment value.","jir_financial_highlights":"Amount of funds raised: \u00a5791,865,000 (Newly raised)\nNumber of new shares issued: 1,000,000 shares (New issuance)\nNumber of stock acquisition rights: 10,500 units (New issuance)","jir_category":"","jir_hashtags":"#Stellapharma, #CapitalPolicy, #JapaneseStocks","jir_key_figures":"Funds raised: approximately \u00a5779 million\nNumber of new shares issued: 1,000,000 shares\nNumber of stock acquisition rights: 10,500 units","jir_meta_title":"\u3010Stellapharma\u3011Fundraising Plan and Share Issue\uff5cJune 2026","jir_meta_description":"Stellapharma plans to raise approximately \u00a5779 million in June 2026. Details of the share issuance, use of funds, and business expansion strategies are explained in detail.","jir_og_title":"\u3010Stellapharma\u30112026 Fundraising and Share Issue Plan","jir_og_description":"Stellapharma will conduct fundraising of approximately \u00a5779 million in June 2026. Funds will be allocated to clinical trials and overseas expansion to support business growth.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59263,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-61795","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n